Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?
Tolvaptan is a highly selective vasopressin receptor 2 antagonist that regulates cyclic adenosine monophosphate levels to inhibit both epithelial cell proliferation and chloride ion excretion, two mechanisms known to induce cyst expansion in autosomal dominant polycystic kidney disease (ADPKD). Tolv...
Furkejuvvon:
| Váldodahkkit: | , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Korean Society of Pediatric Nephrology
2023-12-01
|
| Ráidu: | Childhood Kidney Diseases |
| Fáttát: | |
| Liŋkkat: | http://www.chikd.org/upload/ckd-23-021.pdf |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|